5th Gene Therapy for Neurological Disorders Europe

The 5th Gene Therapy for Neurological Disorders Europe is dedicated to the development and delivery of neurological gene therapies.

The 5th Gene Therapy for Neurological Disorders Europe covers topics such as:

• Safety and toxicity strategies to navigate off target effects including redosing options
• The biology behind AAV toxicity in the CNS
• Vector discovery strategies used to identify vectors with improved CNS tropism and specificity
• Delivery devices to identify novel innovations and areas for development
• Indications being targeted by gene therapies such as neuropathic pain, epilepsy and hearing disorders

The 5th Gene Therapy for Neurological Disorders Europe brings together preclinical, discovery, translational and clinical industry scientists.

The 5th Gene Therapy for Neurological Disorders Europe might be held in 2024.